Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

July 14, 2021 Auto Bot Clinical Trials, P-I 0

Shots:

  • The first patient has been dosed in the P-I ANTLER trial evaluating CB-010 in patients with r/r B-NHL. In the dose-escalation part of the study, patients who have failed at least 2L of CT or immunotherapy will receive the therapy following lymphodepletion
  • The initial purpose of the dose escalation is to evaluate the safety & tolerability of CB-010 while an expansion part of the study is to evaluate the efficacy of CB-010 in a defined population. The results from the trial are expected in 2022
  • CB-010 is an allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells which have developed using Caribou’s chRDNA CRISPR technology

Click here to read full press release/ article | Ref: Businesswire | Image: BioSpace

The post Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma first appeared on PharmaShots.